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Abstract
Background: A lack of cell or tissue sources hampers regenerative medicine for articular cartilage damage.
Main text: We review and discuss the possible use of pluripotent stem cells as a new source for future clinical use.
Human induced pluripotent stem cells (hiPSCs) have several advantages over human embryonic stem cells (hESCs).
Methods for the generation of chondrocytes and cartilage from hiPSCs have been developed. To reduce the cost of
this regenerative medicine, allogeneic transplantation is preferable. hiPSC-derived cartilage shows low immunogenicity
like native cartilage, because the cartilage is avascular and chondrocytes are segregated by the extracellular matrix. In
addition, we consider our experience with the aberrant deposition of lipofuscin or melanin on cartilage during the
chondrogenic differentiation of hiPSCs.
Short conclusion: Cartilage generated from allogeneic hiPSC-derived cartilage can be used to repair articular cartilage
damage.
Keywords: Chondrocytes, Articular cartilage, Regeneration, Induced pluripotent stem cells, Transplantation
Background
Articular cartilage covers the ends of bones and composes
joints, providing lubrication between opposing bones dur-
ing joint motion. Cartilage is avascular and consists of
chondrocytes embedded in abundant extracellular matrix
(ECM), in which collagen fibrils form three-dimensional
(3D) networks that provide scaffolding for proteoglycan.
One function of cartilage ECM is to confer mechanical
properties to cartilage tissue in order to sustain smooth
joint motion. Chondrocytes and cartilage ECM have a
mutually dependent relationship: Chondrocytes produce
and maintain ECM, and ECM is necessary for the chon-
drocytes to sustain their chondrocytic property including
the production of cartilage ECM. This mutual relationship
is indispensable for the homeostasis of cartilage. Cartilage,
when damaged through trauma, has only limited capacity
for repair, probably because the damage causes a loss of
cartilage ECM, disrupting the chondrocytic environment.
The continued use of joints with damaged cartilage and
poor repair capacity gradually expands the damaged area
on the joint surface, resulting in debilitating conditions
such as osteoarthritis.
Current regenerative treatments for articular cartilage
damage
Microfracture is the preferred treatment when the size of
the articular cartilage defect is relatively small (less than 2–
4 cm2). In this treatment, the damaged area of the cartilage
is removed to create a defect, and small holes are made
through the subchondral bone, which allows bone marrow
cells to fill the defect. However, the resulting repair tissue
made by the bone marrow cells is fibrous, which is not as
functional as articular cartilage. Mosaicplasty is another
preferred treatment for small defects. Here, multiple au-
tologous cylindrical osteochondral grafts are harvested
from the periphery of the articular surface and implanted
into the damaged area. Mosaicplasty has the advantage of
transplanting viable hyaline-like cartilage. Nevertheless, this
technique is restricted by the availability of harvestable
autologous graft and by the donor-site morbidity [1]. For
larger articular cartilage defects, autologous chondrocyte
transplantation (ACI) is preferred. Here, a small piece of
cartilage is harvested from the periphery of the articular
surface and subjected to treatment for the isolation of its
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chondrocytes. These chondrocytes are then expanded in
monolayer culture and transplanted into the damaged area
[2]. Although ACI provides good clinical results, it has lim-
itations. The isolation of chondrocytes from cartilage ECM
in culture causes a loss of the chondrocytic property and
results in the conversion of the chondrocytes to fibroblastic
cells [3–5]. Thus, the repaired tissue includes fibrous tissue,
which has inferior joint function compared with articular
cartilage [6]. Further, the transplanted cells constitute only
a limited portion of the repaired tissue, while the remain-
der is composed of host cells. In fact, the benefit of the
transplanted cells may partly come from the secretion of
factors that stimulate the host cells, i.e., trophic effects. In
addition to the physiology of the repair, another demerit of
ACI is that patients are burdened with sacrificing donor
sites and two-stage surgery.
Mesenchymal stem cells (MSCs) are alternative cell
sources for cartilage repair. MSCs can be obtained from
the bone marrow, adipose tissue, and synovium. Although
MSCs have an ability to be differentiated toward chondro-
cytes, this ability tends to be lost after expansion [7].
Evidence that transplanted MSC-derived chondrocytes
constitute repaired cartilage in vivo is scant, and, like ACI,
the effects of the transplanted MSCs are considered
trophic, in which secreted factors from the MSCs stimulate
host cells to repair the tissue [8–10].
Because the repair mechanism of ACI and MSC trans-
plantation involves trophic factors that act on host cells,
microfracture is often employed with these methods to
provide host cells from the bone marrow. However,
whatever the stimulation, there is a limitation in the
quality of the repair tissue so long the treatment de-
pends on host cells for the creation of repair tissue.
The transplantation of allogeneic cartilage could resolve
the scarcity of cells and the poor chondrocytic property of
the transplants. Allogeneic cartilage transplantation is
distinct from ACI or MSC transplantation in that the trans-
plants are not mere cells, but actual cartilage tissue that can
constitute most of the repair. Cartilage is considered immu-
noprivileged tissue [11, 12] because it lacks vasculature and
because chondrocytes are embedded in the ECM, protect-
ing the cells from immunological reactions. Indeed, allo-
geneic cartilage harvested from juveniles [12–16] have been
transplanted successfully to treat defects. However, the lack
of donors, the heterogeneous quality of the cartilage, and
the risk of disease transmission are all limitations associated
with allogeneic sources.
Chondrocytes and cartilage generated from pluripotent
stem cells as a source for regenerative medicine
The scarcity of allogeneic sources could potentially be
resolved with human pluripotent stem cells (hPSCs)
such as human embryonic stem cells (hESCs) [17] and hu-
man induced pluripotent stem cells (hiPSCs) [18]. ESCs and
iPSCs share characteristic properties, such as pluripotency
and self-renewal, and can be maintained in identical culture
conditions. However, they differ in their preparation: ESCs
are acquired from inner cell mass of embryos, while iPSCs
are somatic cells, such as skin cells or blood cells, that have
been reprogrammed to the pluripotent state by the intro-
duction of specific factors [19]. Methods for the differenti-
ation of both cells toward chondrocytes have been
developed and are interchangeable. Because hESCs and
hiPSCs can be expanded almost infinitely due to their
self-renewal capacity, a large number of chondrocytes can
be prepared. In fact, it is now possible to generate enough
chondrocytes of good quality for regenerative medicine at
the experimental level, although several issues must be
resolved before translating these experimental findings to
the clinic.
Autologous vs. allogeneic transplantation
One advantage of hiPSCs over hESCs is that their creation
does not involve the destruction of an embryo, thus avoiding
certain ethical controversies. Another merit is that hiPSCs
can be made from the patient’s own cells, permitting the
possibility of autologous transplants [20]. However, the prep-
aration of patient-iPSCs and subsequent differentiation
under good manufacturing practice (GMP) guidelines is
costly. To reduce the cost and to provide treatment to a large
population, a bank of allogeneic clinical GMP grade hiPSC
lines is being established [21, 22]. To reduce the risk of im-
mune rejection during the transplantation of tissues gener-
ated from allogeneic hiPSCs, this iPSC library is prepared
from donors homozygous for major HLA types. It is much
easier to prepare homozygous HLA hiPSCs than hESCs,
because it is easier to find individuals who bear homozygous
HLA types and are willing to donate their somatic cells for
iPSC generation compared with embryos for ESC generation.
It is estimated that a bank of 1, 50, and 140 cell lines homo-
zygous for major HLA types from Japan would respectively
match 17, 73, and 90% of the population [22].
As explained above, cartilage is considered to have low
immunogenicity, and the transplantation of allogeneic car-
tilage has been performed in a large number of patients
without matching for HLA types and without the adminis-
tration of immunosuppressive drugs. The transplantation
of allogeneic, particulated juvenile articular cartilage has
given good clinical results [14], although the long-term
clinical outcome remains to be investigated. Cartilage can
be generated from hiPSCs by making hiPSC-derived chon-
drocytes that produce and deposit ECM around themselves
in 3D culture [23, 24]. The avascular structure of cartilage
and ECM produced from the chondrocytes prevent a recip-
ient’s immune cells from contacting the chondrocytes in
the transplanted hiPSC-derived cartilage. Mixed lympho-
cyte reaction assays have shown that hiPSC-derived cartil-
age has the low immunogenicity of human cartilage [25].
Yamashita et al. Inflammation and Regeneration  (2018) 38:17 Page 2 of 7
Moreover, hiPSC-derived chondrocytes are more similar to
juvenile chondrocytes than to adult chondrocytes, and it
has been reported that cartilage from juveniles have more
anabolic activity and are less antigenic than those from
adults [12, 16, 26]. These findings imply that cartilage pre-
pared from a single allogeneic hiPSC or hESC clone could
be used for all patients, which would standardize the quality
and lower the cost of this regenerative medicine.
Generation of cartilage from hiPSCs
The basic principle in currently available protocols for the
chondrogenic differentiation of PSCs is to direct cell fate to
chondrocytic lineage and to eliminate non-chondrocytic
cells [20, 27–29]. To realize this scheme, the composition
of the culture medium and supplements, including growth
factors such as TGF-β, BMP, WNT, and FGF; the cell dens-
ity; and the coating of the dishes on which the cells are
grown must be considered.
We previously developed a method to generate cartilage
from hiPSCs [23, 24]. hiPSCs in adhesion culture were ini-
tially differentiated into mesendodermal cells in the pres-
ence of WNT and Activin. Then, the cells were
differentiated into chondrocytes in chondrogenic medium
containing TGF-β, BMP-2, and GDF-5. The resulting chon-
drocytes were subsequently transferred into 3D suspension
culture in which the chondrocytes secreted and accumu-
lated cartilage ECM around themselves to create cartilagin-
ous tissues that look like white particles of 2–3 mm
diameter (Fig. 1a, b). Histological analysis of each particle
showed that the particles consisted of central cartilaginous
tissue and were surrounded by membranous tissue (Fig. 1c).
This structure may correspond to cartilage surrounded by
perichondrium. Although the observation periods are lim-
ited, transplantation of the hiPSC-derived cartilage into ar-
ticular cartilage defects in immunodeficient rats and
immunosuppressed mini-pigs showed that the transplanted
cartilage survived and had potential for integration into na-
tive cartilage [24]. These results suggest that hiPSC-derived
cartilage can be used to repair articular cartilage damage.
Aberrant deposition of lipofuscin or melanin during
chondrogenic differentiation of hiPSCs
Protocols for chondrogenic differentiation should be
robust and produce cartilage of high quality. However, it
Fig. 1 Generation of cartilaginous particles from hiPSCs. a Scheme of the chondrogenic differentiation of hiPSCs. b Image of a hiPSC-derived
cartilaginous particle at 12 weeks. c Histological analysis of the hiPSC-derived cartilaginous particle at 12 weeks. Semiserial sections were stained
with hematoxylin-eosin and safranin O-fast green-iron hematoxylin and immunostained with anti-type II collagen antibodies and anti-type I
collagen antibodies. Bars, 50 μm.
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is known in the field that culture does not always go as
expected. As an example, we have observed unexplained
dark dots on the surface of some hiPSC-derived cartil-
aginous particles on rare occasion (Fig. 2a). This
phenomenon was observed in several independent hiPSC
lines. The presence of malaria pathogens and formalin is
known to cause artificial dark pigments (Table 1), but cul-
ture conditions are free of these substances. Thus, to ex-
plain these dots, we investigated natural pigmentations
(Table 1) [30]. Histological analysis revealed that the dark
dots resided in the cytoplasm of cells located on the sur-
face of the particles (Fig. 2b). The dark dots lost color after
bleaching by treatment with potassium permanganate,
Fig. 2 Aberrant emergence of dark dots on the surface of hiPSC-derived
cartilaginous particles. a Image of a hiPSC-derived cartilaginous particle
with dark dots at 12 weeks. b Histological analysis of the hiPSC-derived
cartilaginous particle in a. Semiserial sections were stained with
hematoxylin-eosin and safranin O-fast green-iron hematoxylin. Arrows
indicate dark dots. Bars, 50 μm.
Table 1 Pigments
Source Pigment type Color
Hematogenous Hemoglobin Red to brown
Hemosiderin Yellow to brown
Bile Yellow to brown
Porphyrin Dark brown
Non-hematogenous Melanin Brown to black
Chromaffin Dark brown
Lipofuscin Yellow to brown
Artifact Malaria Dark brown
Formalin Dark brown
Fig. 3 Analysis of dark dots on hiPSC-derived cartilaginous particles.
Histological analysis of a hiPSC-derived cartilaginous particle with dark
dots at 12 weeks. a Sections were bleached and counterstained with
kernechtrot. b Sections were initially bleached weakly and subjected
to PAS staining, Giemsa staining, and Schmorl’s reaction. Bars, 50 μm.
Boxed regions are magnified in the images below.
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suggesting they are not hematogenous pigments, which
are resistant to bleaching [31] (Fig. 3a). Among
non-hematogenous pigments, melanin, chromaffin, and
lipofuscin look dark and are sensitive to bleach [32, 33].
These three pigments can be discriminated by reactions to
PAS staining, Schmorl’s reaction, and Giemsa staining
(Table 2) [32–35]. Further investigation found that the
dark dots were positively stained with Schmorl [34].
Giemsa staining indicated dark blue [35], but we could not
rule out that it indicated dark green (Fig. 3b). The area
stained by PAS overlapped the dark dots, although not
completely. Based on these findings, we considered the
dark dots on the surface of hiPSC-derived cartilage to be
either lipofuscin or possibly melanin. Either case could
compromise the use of these particles for regenerative
medicine.
Lipofuscin is a cross-linked aggregate that consists of
oxidized proteins and lipids and is resistant to cellular
proteolytic systems [36, 37]. Lipofuscin is insoluble and
is not exocytosed by cells such that it resides in the cyto-
sol. Lipofuscin is found in postmitotic cells in various
tissues and organs and has two sources. One is damaged
mitochondria caused by a malfunction of the mitochon-
drial repair system due to aging and/or excess amounts
of reactive oxygen species (ROS). The other is damaged
proteins, such as oxidized proteins and unfolded pro-
teins that cross-link in the cytosol. Normally, these dam-
aged particles are taken up by lysosomes and degraded.
A failure in this degradation leads to the damaged mito-
chondria and proteins within the lysosomes cross-
linking and binding more particles, such as lipids, to
produce lipofuscin. Lipofuscin enters the cytosol if the
lysosomes rupture. There, lipofuscin may disturb cell func-
tion and consume both lysosomal enzyme capacity and
lysosomal space, further reducing lysosomal degradation
capacity. Furthermore, it may have a chemically reactive
surface that can disturb cellular metabolism. Lipofuscin has
been reported to accumulate in natural cartilage [38]. Al-
though the effects of lipofuscin on cartilage metabolism are
unknown, culture conditions that produce no lipofuscin
should be used for repairing cartilage damage.
The mechanism by which dark dots aberrantly form
during the chondrogenic differentiation of hiPSCs
remains to be elucidated. We found the dark dots
reproducibly appeared when we increased cell density
during the differentiation of hiPSCs toward chondro-
cytes. Consistently, dark dots did not appear when
the differentiation protocol was done without cell
overgrowth. It has been reported that lipofuscin forms
in the chondrogenic micromass culture of chick limb
bud mesenchymal cells when they are treated with
agents that increase the generation of OH(.) radicals
[39]. Whether the generation of OH(.) radicals con-
tributes to the dark dots seen with cell overgrowth
during the chondrogenic differentiation of hiPSCs re-
mains to be determined.
On the other hand, if the dark dots are due to the
presence of melanin, then it is likely that a differenti-
ated subpopulation took the melanocyte fate. It is un-
known whether here too cell densities could have an
effect. The contamination of melanocytes in the
hiPSC-derived cartilage would inevitably compromise
the repair process after transplantation because this
subpopulation does not have chondrogenic function.
Whichever causes the dark dots (lipofuscin or mel-
anin), cartilage particles generated from iPSCs should
avoid their presence when considering the repair of
articular cartilage damage.
Conclusions
Cartilage is a tissue that consists of chondrocytes and
ECM, which are mutually dependent. The healing mech-
anisms by cell transplantation such as ACI or MSC
transplantation into articular cartilage defects may de-
pend on trophic effects, whereas the transplantation of
cartilage tissue can produce repair tissue of good quality.
hiPSCs promise a new generation of cartilage therapy.
Cartilage tissue can be produced by the differentiation of
hiPSCs into chondrocytes followed by transferring the
cells into 3D suspension culture in which the chondro-
cytes secrete and accumulate surrounding cartilage
ECM. hiPSC-derived cartilage has low immunogenicity
like natural cartilage and can be transplanted in an allo-
geneic manner for the treatment of articular cartilage
damage. The differentiation of iPSCs to cartilage should
be tightly controlled to avoid the presence of non-carti-
laginous elements such as lipofuscin or melanin.
Table 2 Pigments and staining methods
Non-hematogenous pigment Hematogenous pigment
Staining Lipofuscin Melanin Chromaffin
Bleach Sensitive Sensitive Weakly sensitive Resistant
PAS Positive Negative Negative Negative
Giemsa Ortho-chromasia (dark blue) Meta-chromasia (dark green) Meta-chromasia (red purple)
Schmorl’s reaction Positive Positive Weakly positive
Berlin blue Negative Negative Negative Positive (hemosiderin)
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Methods
Chondrogenic differentiation of hiPSCs
Cartilaginous particles were generated from hiPSCs as de-
scribed previously [24] with modification. hiPSCs-derived
cartilaginous particles generated 12 weeks after the start
of the differentiation were used.
Histological analysis
hiPSC-derived cartilaginous particles were fixed with 4%
paraformaldehyde, processed, and embedded in paraffin.
Semiserial sections were stained with hematoxylin-eosin
and safranin O-fast green-iron hematoxylin and immuno-
stained with anti-type II collagen antibody and goat
anti-type I collagen antibody, as described previously [24].
Semiserial sections were bleached with 0.25% potassium
permanganate (Nacalai) for 1 h, then with 2% oxalic acid
for 2 min, and finally counterstained with kernechtrot
(Muto pure chemicals).
For Schmorl’s reaction, PAS staining, and Giemsa
staining, semiserial sections were initially weakly
bleached with 0.25% potassium permanganate (Naca-
lai) for 3 min and 2% oxalic acid for 2 min. The sec-
tions were subjected to Schmorl’s reaction by being
stained with ferric chloride (Wako) and counter-
stained with kernechtrot. The sections were subjected
to PAS staining by being treated with Schiff ’s reagent
(Wako) for 10 min and counterstained with
hematoxylin. Finally, the sections were subjected to
Giemsa staining by being stained with Giemsa stain
solution composed of Giemsa (Merck), methanol, and
sodium carbonate (Nacalai) for 3 h.
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